RU2016138744A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2016138744A3 RU2016138744A3 RU2016138744A RU2016138744A RU2016138744A3 RU 2016138744 A3 RU2016138744 A3 RU 2016138744A3 RU 2016138744 A RU2016138744 A RU 2016138744A RU 2016138744 A RU2016138744 A RU 2016138744A RU 2016138744 A3 RU2016138744 A3 RU 2016138744A3
- Authority
- RU
- Russia
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
- C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461977824P | 2014-04-10 | 2014-04-10 | |
| US61/977,824 | 2014-04-10 | ||
| US201462057381P | 2014-09-30 | 2014-09-30 | |
| US62/057,381 | 2014-09-30 | ||
| PCT/US2015/025305 WO2015157629A2 (en) | 2014-04-10 | 2015-04-10 | Antibodies, pharmaceutical compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2016138744A RU2016138744A (ru) | 2018-05-11 |
| RU2016138744A3 true RU2016138744A3 (enExample) | 2018-05-11 |
Family
ID=54288553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016138744A RU2016138744A (ru) | 2014-04-10 | 2015-04-10 | Антитела, фармацевтические композиции и их применения |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9902779B2 (enExample) |
| EP (2) | EP3129048B1 (enExample) |
| JP (1) | JP2017512759A (enExample) |
| KR (1) | KR101966408B1 (enExample) |
| CN (2) | CN112390887B (enExample) |
| AU (2) | AU2015243246B2 (enExample) |
| BR (1) | BR112016020009A2 (enExample) |
| CA (2) | CA3104268A1 (enExample) |
| CL (1) | CL2016002569A1 (enExample) |
| ES (1) | ES2772817T3 (enExample) |
| IL (2) | IL246837B (enExample) |
| PH (1) | PH12016501976A1 (enExample) |
| RU (1) | RU2016138744A (enExample) |
| SG (1) | SG11201607258SA (enExample) |
| TW (3) | TWI697503B (enExample) |
| WO (1) | WO2015157629A2 (enExample) |
| ZA (1) | ZA201605175B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ714555A (en) | 2013-09-17 | 2020-03-27 | Obi Pharma Inc | Compositions of a carbohydrate vaccine for inducing immune responses and uses thereof in cancer treatment |
| TW201622743A (zh) | 2014-03-19 | 2016-07-01 | 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 | 免疫原醣肽、包含該醣肽之組合物及其用途 |
| EP3129048B1 (en) | 2014-04-10 | 2020-01-15 | OBI Pharma Inc. | Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof |
| EP3344806A4 (en) | 2015-09-04 | 2019-03-20 | OBI Pharma, Inc. | GLYCANARRAYS AND METHOD OF USE |
| BR112018006140A2 (pt) * | 2015-10-07 | 2018-10-23 | Obi Pharma Inc | anticorpo ou uma porção de ligação a antígeno do mesmo, composição farmacêutica, e, método para inibição de proliferação de células cancerígenas. |
| BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| CA3021548A1 (en) | 2016-04-22 | 2017-10-26 | Obi Pharma, Inc. | Cancer immunotherapy by immune activation or immune modulation via globo series antigens |
| GB201612317D0 (en) * | 2016-07-15 | 2016-08-31 | Philogen Spa | Antibody compositions |
| AU2017302038B2 (en) | 2016-07-27 | 2024-03-21 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
| KR102528998B1 (ko) | 2016-07-29 | 2023-05-03 | 오비아이 파머 인코퍼레이티드 | 인간 항체, 제약 조성물 및 방법 |
| US11000601B2 (en) * | 2016-11-21 | 2021-05-11 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
| WO2018218068A1 (en) * | 2017-05-24 | 2018-11-29 | Development Center For Biotechnology | Humanized antibodies against globo h and uses thereof in cancer treatments |
| KR20200131846A (ko) | 2018-03-14 | 2020-11-24 | 메모리얼 슬로안 케터링 캔서 센터 | 항-폴리시알산 항체 및 그 용도 |
| WO2019232519A1 (en) * | 2018-06-01 | 2019-12-05 | Obi Pharma, Inc. | Combination therapy by using anti-globo h or anti-ssea-4 antibody with anti-negative immune check points antibody |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| WO2020198699A2 (en) * | 2019-03-28 | 2020-10-01 | Obi Pharma, Inc. | Companion diagnostic assay for globo-h related cancer therapy |
| CA3204922A1 (en) * | 2021-02-09 | 2022-08-18 | Ming-Tain Lai | Globo series antigens-binding chimeric antigen receptors and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| CA2119930C (en) | 1991-09-23 | 2002-10-01 | Hendricus R. J. M. Hoogenboom | Production of chimeric antibodies - a combinatorial approach |
| AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
| AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
| EP1150710B1 (en) | 1999-02-17 | 2010-04-21 | Csl Limited | Immunogenic complexes and methods relating thereto |
| CA2406993A1 (en) | 2000-03-24 | 2001-09-27 | Micromet Ag | Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| DE60124912T2 (de) * | 2001-09-14 | 2007-06-14 | Affimed Therapeutics Ag | Multimerische, einzelkettige, Tandem-Fv-Antikörper |
| BR0107262B1 (pt) | 2001-12-17 | 2014-04-22 | Da Fonseca Clovis Orlando Pereira | Composição farmacêutica inalatória |
| US20040126829A1 (en) | 2001-12-18 | 2004-07-01 | Hildebrand William H. | Anti-HLA assay and methods |
| EP1505075B1 (en) * | 2002-04-30 | 2009-10-07 | Kyowa Hakko Kirin Co., Ltd. | Antibody to human insulin-like growth factor |
| CA2487932A1 (en) * | 2002-05-30 | 2003-12-11 | Macrogenics, Inc. | Cd16a binding proteins and use for the treatment of immune disorders |
| AT413486B (de) * | 2002-07-03 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung eines antikörpers gerichtet gegen lewis-antigene |
| DK2270045T3 (en) | 2004-02-06 | 2015-04-07 | Univ Massachusetts | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINES AND APPLICATIONS THEREOF |
| CA2601417C (en) * | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
| EP2484374A1 (en) | 2004-07-18 | 2012-08-08 | CSL Limited | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
| JP2008506683A (ja) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ， リミテッド | 先天免疫応答を誘導するための方法および組成物 |
| AU2005319382B2 (en) * | 2004-12-21 | 2011-04-07 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| MX2007008619A (es) * | 2005-02-07 | 2007-09-11 | Glycart Biotechnology Ag | Moleculas de union al antigeno que fijan egfr, vectores que las codifican y usos de las mismas. |
| US7812135B2 (en) * | 2005-03-25 | 2010-10-12 | Tolerrx, Inc. | GITR-binding antibodies |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| PL1920781T3 (pl) | 2006-11-10 | 2015-06-30 | Glycotope Gmbh | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów |
| WO2008087259A1 (en) * | 2007-01-18 | 2008-07-24 | Suomen Punainen Risti, Veripalvelu | Novel carbohydrate profile compositions from human cells and methods for analysis and modification thereof |
| CA2728344A1 (en) | 2008-06-16 | 2010-01-14 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| JP5216139B2 (ja) | 2008-06-16 | 2013-06-19 | アカデミア シニカ | ＧｌｏｂｏＨおよびその断片に対する抗体のレベルに基づく癌の診断方法 |
| TWI392502B (zh) * | 2009-06-16 | 2013-04-11 | Academia Sinica | 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗 |
| EP2462161B1 (en) * | 2009-08-06 | 2017-03-08 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| JP5906233B2 (ja) * | 2010-04-09 | 2016-04-20 | アベオ ファーマシューティカルズ， インコーポレイテッド | 抗ＥｒｂＢ３抗体 |
| CA2803222A1 (en) * | 2010-07-01 | 2012-01-05 | Dsm Ip Assets B.V. | A method for the production of a compound of interest |
| US8999343B2 (en) * | 2010-08-16 | 2015-04-07 | Amgen Inc. | Antibodies that bind myostatin, compositions and methods |
| TW201307388A (zh) * | 2010-12-21 | 2013-02-16 | Abbott Lab | Ｉｌ－１結合蛋白 |
| EP2497782A1 (en) * | 2011-03-08 | 2012-09-12 | Alzinova AB | Anti oligomer antibodies and uses thereof |
| US9828635B2 (en) | 2011-10-06 | 2017-11-28 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| CN104520324A (zh) | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| US9982041B2 (en) | 2014-01-16 | 2018-05-29 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| TW201622743A (zh) | 2014-03-19 | 2016-07-01 | 財團法人臺灣基督長老教會馬偕紀念社會事業基金會馬偕紀念醫院 | 免疫原醣肽、包含該醣肽之組合物及其用途 |
| EP3129048B1 (en) | 2014-04-10 | 2020-01-15 | OBI Pharma Inc. | Antibodies binding to tumour associated carbohydrate antigens, pharmaceutical compositions and uses thereof |
-
2015
- 2015-04-10 EP EP15777370.6A patent/EP3129048B1/en active Active
- 2015-04-10 CN CN202011258954.4A patent/CN112390887B/zh active Active
- 2015-04-10 TW TW106128654A patent/TWI697503B/zh active
- 2015-04-10 US US15/303,132 patent/US9902779B2/en active Active
- 2015-04-10 TW TW104111557A patent/TWI609886B/zh active
- 2015-04-10 AU AU2015243246A patent/AU2015243246B2/en not_active Ceased
- 2015-04-10 RU RU2016138744A patent/RU2016138744A/ru not_active Application Discontinuation
- 2015-04-10 WO PCT/US2015/025305 patent/WO2015157629A2/en not_active Ceased
- 2015-04-10 CA CA3104268A patent/CA3104268A1/en not_active Abandoned
- 2015-04-10 BR BR112016020009A patent/BR112016020009A2/pt not_active IP Right Cessation
- 2015-04-10 ES ES15777370T patent/ES2772817T3/es active Active
- 2015-04-10 EP EP20151337.1A patent/EP3662928A1/en not_active Withdrawn
- 2015-04-10 JP JP2016554855A patent/JP2017512759A/ja active Pending
- 2015-04-10 TW TW106128651A patent/TWI695013B/zh active
- 2015-04-10 CN CN201580011286.6A patent/CN106456727B/zh active Active
- 2015-04-10 SG SG11201607258SA patent/SG11201607258SA/en unknown
- 2015-04-10 KR KR1020167024072A patent/KR101966408B1/ko not_active Expired - Fee Related
- 2015-04-10 CA CA2941029A patent/CA2941029C/en active Active
-
2016
- 2016-07-19 IL IL246837A patent/IL246837B/en active IP Right Grant
- 2016-07-25 ZA ZA2016/05175A patent/ZA201605175B/en unknown
- 2016-10-04 PH PH12016501976A patent/PH12016501976A1/en unknown
- 2016-10-07 CL CL2016002569A patent/CL2016002569A1/es unknown
-
2017
- 2017-11-28 US US15/824,733 patent/US10815307B2/en active Active
-
2018
- 2018-10-26 AU AU2018253589A patent/AU2018253589B2/en not_active Ceased
-
2020
- 2020-08-13 IL IL276695A patent/IL276695B/en unknown
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20180704 |